Jesper Stentoft
Overview
Explore the profile of Jesper Stentoft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holst J, Pedersen M, Enemark M, Hansen M, Noerhave P, Plesner T, et al.
Haematologica
. 2024 Jul;
109(12):4067-4072.
PMID: 39049601
No abstract available.
2.
Flygt H, Soderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, et al.
Leukemia
. 2024 Feb;
38(4):925.
PMID: 38418611
No abstract available.
3.
Stentoft J
Br J Haematol
. 2024 Feb;
204(4):1139-1140.
PMID: 38375783
Clinical research has not been able to establish whether the differences between first- and second-generation BCR-ABL 1 kinase inhibitors are clinically relevant with regard to outcome. In the study by...
4.
Flygt H, Soderlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, et al.
Leukemia
. 2024 Jan;
38(4):781-787.
PMID: 38278960
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular...
5.
Svingel L, Christensen S, Kjaersgaard A, Stenling A, Paulsson B, Andersen C, et al.
Acta Oncol
. 2023 Sep;
62(10):1286-1294.
PMID: 37656802
Background: Patients with myeloproliferative neoplasms (MPNs) suffer from substantial symptoms and risk of debilitating complications, yet observational data on their labor market affiliation are scarce. Material And Methods: We conducted...
6.
Huuhtanen J, Ilander M, Yadav B, Dufva O, Lahteenmaki H, Kasanen T, et al.
J Clin Invest
. 2022 Sep;
132(17).
PMID: 36047494
In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-α is one promising...
7.
Christensen S, Svingel L, Kjaersgaard A, Stenling A, Darvalics B, Paulsson B, et al.
Eur J Haematol
. 2022 Jul;
109(5):526-541.
PMID: 35900040
Few studies have assessed healthcare resource utilization (HRU) in patients with Philadelphia-negative myeloproliferative neoplasms (MPN) using a matched cohort design. Further, no detailed assessment of HRU in the years preceding...
8.
Hasselbalch H, Knudsen T, Sorensen A, Christensen S, Larsen M, Bak M, et al.
Ugeskr Laeger
. 2021 Oct;
183(42).
PMID: 34709157
Recent studies have shown the Philadelphia-negative myeloproliferative neoplasms (MPN) to be massively underdiagnosed and often preceded by a long pre-diagnostic phase of several years, in which many patients suffer serious...
9.
Knudsen T, Skov V, Stevenson K, Werner L, Duke W, Laurore C, et al.
Blood Adv
. 2021 Sep;
6(7):2107-2119.
PMID: 34507355
Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing...
10.
Flygt H, Soderlund S, Stentoft J, Richter J, Koskenvesa P, Mustjoki S, et al.
Eur J Haematol
. 2021 Aug;
107(6):617-623.
PMID: 34418168
Objectives: Treatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of...